Madeleine Strickland

Madeleine Strickland has over 10 years of work experience in the field of biochemistry. Madeleine began their career in 2008 as a PhD Student in Chemistry at the University of Bristol, where they studied the interaction between insulin-like growth factor 2 (IGF2) and its receptor IGF2R. In 2012, they moved to Universit\u00e9 de Strasbourg as a Post-doctoral Researcher, where they used infrared, Raman, and UV-visible spectroscopy to study proteins that are difficult to study by other techniques. In 2014, they joined the National Heart, Lung, and Blood Institute as a Visiting Fellow, where they developed an interest in paramagnetism for use in the study of large and dynamic biomolecular complexes. In 2020, they joined Skyhawk Therapeutics as a Principal Scientist and Senior Scientist.

Madeleine Strickland has a long and varied educational background. Madeleine obtained their Doctor of Philosophy (PhD) in Chemistry from the University of Bristol in 2012, after completing an MSci in Chemistry With Study in Continental Europe (Italy) in 2008. Madeleine also completed an Erasmus in Chemistry at the Università degli Studi di Perugia in 2006-2007. In 2002-2004, they completed A-level studies in Chemistry, Biology, Maths, and Music AS at Peter Symond's College, Winchester, UK. Madeleine also earned GCSEs in Triple science, Maths, Double English, Italian, German, Music, Theirtory, Design & Technology from Kings School, Winchester, UK in 1997-2002. In 2021, they became a Member of the Royal Society of Chemistry.